Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Issue 5 (3rd May 2016)

• Record Type: Journal Article
• Authors: Goebeler, Maria-Elisabeth; Bargou, Ralf
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 5(2016:May)
• Page Start: 1021
• Page End: 1032
• Publication Date: 2016-05-03
• Subjects: B-precursor ALL -- BiTE® -- blinatumomab -- immunotherapy -- NHL; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2016.1161185
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent activity in patients with relapsed and/or refractory (R/R) non-Hodgkin lymphoma and R/R B cell precursor acute lymphoblastic leukemia (B-precursor ALL). Cytokine release syndrome and neurological side effects were dose-limiting. Adverse effects were well manageable and transient in nature. Based on results of an international phase II trial, blinatumomab received FDA approval for the treatment of R/R B-precursor ALL in December 2014. Ongoing and future trials will contribute to further optimization of blinatumomab-based T cell therapy and have to show that integration of blinatumomab in current and innovative treatment protocols improves overall survival and quality of life of patients with B cell malignancies.